Use of tiagabine for the treatment of sleep disorders

Abstract: The invention relates to a method of treating sleep disorders in a patient in need thereof comprising the administration of a hypnotically effective amount of a non-allosteric GABA A agonist.

Description: Field of the invention This invention relates to the use of the non-allosteric GABA A agonist tiagabine for the preparation of a medicament for treating sleep disorders. Background The hypnotics most frequently prescribed for the treatment of sleep disorders are classic benzodiazepines as well as compounds like zolpidem and zopiclone. These compounds shorten sleep latency and increase total sleep time. The pharmacological effect of these compounds is assumed to be due to a modulation of the GABA A receptor (γ-aminobutyric-acid A receptor); however they neither increase neuronal release of GABA nor block the reuptake of released GABA. They have no direct GABA A agonistic effect either. On the contrary, they react with specific binding sites which belong to a complex consisting of GABA receptors, various distinct modulatory receptors among others for benzodiazepines and a chloride ion channel, and thus cause the GABA A receptor to undergo an allosteric change. This allosteric change influences the efficacy of GABA in promoting chloride channel opening. However, such GABA A receptor modulators exhibit considerable side effects. Especially with the use of benzodiazepines, tolerance and dependency develop rapidly, and rebound insomnia, which will manifest itself by restlessness and somnipathy, emerges upon withdrawal. Furthermore, the quality of sleep induced by said GABA A receptor modulators is unphysiological. REMS (= rapid eye movement sleep) as well as the deeper phases of nonREMS (slow-wave sleep) are disturbed. For example, benzodiazepines and all other common hypnotics cause the following sleep profile. 1) they inhibit REMS 2) they promote nonREMS 3) they decrease delta activity (0.5-4 Hz) in the EEG within nonREMS by a) reducing the rate of rise of delta activity at the beginning the nonREMS episodes, and b) reducing the maximum delta activity during nonREMS episodes. In one of two studies, Mendelson et al. (Life Sci 47, (1990) 99, 101; Life Sci 53 (1993) 81-87) found that muscimol, a GABA analogue and selective GABA A agonist, does cause a slight reduction of sleep latency but does not influence sleep as such. This finding resulted in the common opinion that non-benzodiazepoid GABA A agonists are devoid of any clinical beneficial effects on sleep disorders. Furthermore, it is generally accepted in the field that if a substance has a sedative side effect or causes a slight reduction in sleep latency, this will not justify its classification as a hypnotic. In Pharmacol. Biochem. and Behaviour (1993), vol 45, pp 881-887, Suzuki et al investigated the effect of 3 mg/kg muscimol IP in different inbred strains of rats (Fischer 344, and Lewis) by measuring the loss and duration of the righting reflex. The authors of this document equate the duration of loss of the righting reflex to an hypnotic effect (sleep time). However, it is well established that the behavioral parameter "righting reflex" bears no relationship with sleep. In the rat, very high doses of muscimol, such as 3 mg/kg, are known to evoke absence epilepsy. It is in fact highly likely that the perceived sedation ("loss of righting reflex") represents a pathological state of an epileptiform nature (see "Hypersynchronisation and Sedation Produced by GABA-Transaminase Inhibitors and picrotoxin: Does GABA Participate in Sleep Control?", Waking and Sleeping (1979), 3: 245-254). In US-A-5,185,446 cycloalkylinidazo pyrimidine derivatives are disclosed which are described as being selective agonists, antagonists or inverse agonists for GABA a brain receptors and may be used in the diagnosis and treatment of anxiety, sleep and other disorders. All of these compounds are, however, allosteric GABA a -receptor modulators. In Pharmacol. Biochem. and Behaviour (1988), vol 29, pp 781-783, the hypnotic effects of the allosteric GABA a -receptor modulators are described. The object underlying the present invention is to provide an effective hypnotic which has no significant side effects and causes a sleep profile essentially corresponding to physiological sleep. Summary of the invention The present invention provides the use of tiagabine for the preparation of a pharmaceutical composition for treating sleep disorders in a patient in need thereof. Detailed description of the invention The present invention is based on the unexpected finding that the GABA A agonists muscimol and THIP (4,5,6,7-tetrahydroisoxazolo(5,4-C) pyridin-3-ol) have very advantageous effects on sleep. The activity profiles of muscimol- and THIP-induced sleep can be summarized as follows: 1) The total duration of nonREMS and REMS is increased after muscimol and THIP increases nonREMS. 2) Prolongation of nonREMS episodes as well as REMS episodes, which supports sleep continuity. 3) The EEG-delta activity within nonREMS is enhanced; this is achieved by a) increasing the rise rate of delta activity at the beginning of each nonREMS episode, b) increasing the maximum delta activity during the nonREMS episodes, and c) prolonging the nonREMS episodes (see 2). All above-summarized changes correspond to the sleep profile observed with a physiological increase in sleep need, for instance, after an extended period of wakefulness. This shows that a non-allosteric GABA A agonist, unlike benzodiadepines and all other common hypnotics, can induce sleep having the characteristics of natural sleep. Results similar to those observed using the full GABA A agonist muscimol and the partial GABA A agonist THIP could also be achieved by using other non-allosteric GABA A agonists, GABA transaminase inhibitors, such as vigabatrin, and GABA uptake inhibitors, such as tiagabine. It was thus found that the pharmacological stimulation of the GABA binding site of the GABA A receptor, either directly by administering a GABA A agonist or indirectly by increasing the endogenous GABA concentration by way of a GABA prodrug, GABA uptake inhibitor or GABA transaminase inhibitor, can be of considerable therapeutic advantage in the treatment of sleep disorders. Thus, the invention relates to the use of the GABA uptake inhibitor tiagabine in the treatment of sleep disorders in a patient in need thereof. Due to its pharmacological properties, tiagabine having an indirect non-allosteric agonistic effect on the GABA A receptor is therapeutically beneficial in a broad range of sleep disorders, including difficulties in falling asleep, frequent nocturnal arousals, early morning awakening and/or a dissatisfaction with the intensity of sleep. Tiagabine is particularly suitable for the treatment of elderly patients. In effecting treatment of a patient afflicted with a sleep disorder in accordance with the method of the invention, the non-allosteric GABA A agonist tiagabine can be formulated in a manner well-known in the art using common pharmaceutical adjuvants and optionally in combination with other active substances to form common galenic preparations, such as tablets, coated tablets, capsules, powders, suspensions, injectable solutions or suppositories. In accordance with the subject matter of the invention, tiagabine can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, tiagabine can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, topically, and the like. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances. Tiagabine can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the solubility and chemical properties of tiagabine, the chosen route of administration, and standard pharmaceutical practice. Tiagabine, while effective itself, may be formulated and administered in the form of its pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like. The dose to be administered depends on the patient's age and weight as well as the degree and nature of sleep disorder. Preferably, tiagabine is administered in a dose of 5 mg to 50 mg per day. The administration may be intravenous or intramuscular. However, oral administration is preferred. As used herein, the term "hypnotically effective amount" means an amount sufficient to reduce sleep latency, prolong REMS, prolong nonREMS, prolong total sleep or enhance EEG-delta activity during sleep. The following comparative examples serve to explain the invention in more detail. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way. Example 1 After intraperitoneal administration of placebo (pyrogen-free saline) or muscimol (0,2 and 0,4 mg/kg), the EEG and EMG as well as the brain temperature of adult rats were continuously recorded. Muscimol resulted in a dose-dependent increase of nonREMS and REMS and a prolongation of REMS and nonREMS episodes. From the analysis of the nonREMS episodes in the EEG spectrum, it became evident that muscimol, in particular in higher doses, increases the EEG activity in all frequency bands, most potently, however, at lower frequencies (0.5 to 4 Hz), thought to reflect sleep intensity. Example 2 After intraperitoneal administration of Placebo (pyrogen-free saline) or THIP (2 and 4 mg/kg), the EEG and EMG as well as the brain temperature of adult rats were continuously recorded. THIP dose-dependently increased the total amount of nonREMS and lengthened the duration of the nonREMS and REMS episodes. The higher dose of THIP elevated delta activity within nonREMS, generally believed to reflect an increase in nonREMS intensity. Corresponding results were also obtained using vigabatrin. Example 3 In a double blind, placebo controlled study the effects of 20 mg THIP administered in gelatine capsules at 22:30 h on sleep in 10 young, healthy male subjects was investigated. The subjects went to bed at 23:00 h and time in bed was not restricted. Compared to the placebo condition, THIP significantly increased sleep efficiency and enhanced total time spent in slow wave sleep (stages 3 and 4) by about 30 minutes. Spectral analysis of the EEG within nonREMS (stages 2, 3 and 4) showed that THIP significantly elevated delta activity (cumulative power in the frequency bins between 0.78 and 4.30 Hz) and depressed sigma activity (cumulative power in the frequency bins between 12.50 and 14.83 Hz, the spindle frequency bands). Analysis of the development of delta and sigma activity over the first 30 minutes of the nonREMS episodes revealed that during THIP delta activity increased more rapidly and reached higher levels, while sigma activity remained below placebo values. These effects are highly similar to those induced by sleep deprivation in humans. The effects of THIP on sleep in young human subjects, with no sleep disturbances, confirm and extend the findings of GABA A agonists in rats and show that THIP, similar to sleep deprivation and in contrast to existing hypnotics, promotes deep nonREMS, without suppressing REMS.

Claims: Use of tiagabine for the preparation of a pharmaceutical composition for treating a sleep disorder. Use according to claim 1 for the treatment of an elderly patient. Use according to claim 1, wherein said sleep disorder is difficulty in falling asleep. Use according to claim 1, wherein said sleep disorder is frequent nocturnal arousal. Use according to claim 1, wherein the amount of tiagabine to be administered is 5 to 50 mg per day.

Inventors: LANCEL MARIKE, LANCEL, MARIKE
Applicants: MAX PLANCK GESELLSCHAFT, MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG<BR>DER WISSENSCHAFTEN E.V.
Application year: 1996
Main classification: A61K31
IPC codes: A61K31